FDMT vs V · rev $37.0K vs P/E 33, rev $40.00B
4D Molecular Therapeutics Inc (FDMT) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
FDMT currently screens at market cap $518.1M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the FDMT and V stock pages for the full models.
Not investment advice.